First Trust Amex Biotech Index Fund (FBT)

On our desk, FBT's equal-weighted mechanism has been a frequent topic of conversation. Unlike cap-weighted alternatives like the XBI, FBT's structure of holding exactly 30 biotechnology companies provides a balanced exposure that avoids heavy reliance on just two or three mega-caps. Watching the recent price action trade near its 52-week highs around $271.87 with a solid 1-year trailing return over 50%, market sentiment is distinctly bullish for investors who have a high risk tolerance for biotech cycles.

From a risk management standpoint, we have to look closely at the underlying valuation multiples cited in the June 2026 data. With a P/E ratio pushing past 30 and price-to-sales sitting near 5.19, this fund is priced for aggressive growth. While the 3-year standard deviation sits at 18.70% and Morningstar rates it 4 stars among health funds, clients must be briefed on historical drawdown phases and regulatory risks inherent to clinical-stage and commercial biotechnology constituents.

In our clinical asset management sessions, we evaluate how equal-weighted thematic ETFs like FBT capture the underlying pipeline execution of firms like Halozyme Therapeutics and Corcept Therapeutics. Because the index rebalances to maintain equal dollar weights across its 30 holdings, it forces automatic buying of underperformers and trimming of winners. Analysts modeling this fund need to understand how constituents move independently of broad indices like the SandP 500, especially given its distinct health sector correlation profile.